Semantic Coherence: CSL – Signal Evidence & AI Readability

[H1] Hear Melissa's HAE Story
For decades, the rare disease Hereditary Angioedema (HAE) overwhelmed Melissa’s days. But today she’s making up for lost time in her new role as a grandmother.
Watch the Video

Like to learn more about Our Impact? Click here to view or download the 2025 Impact Report →   |    Would you like to read our 2025 Annual Report? Click here to view or download the Annual Report →   |    CSL's 2025 Full Year Financial Results Click here for Full Information including Webcast Recording →

CSL
CSL Behring
CSL Seqirus
CSL Vifor

[H2] CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products

[H2] CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring

[H2] CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus

[H2] CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL Vifor

[IMG: CSL Logo]

[H2] CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products

[IMG: CSL Behring Logo]

[H2] CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring

[IMG: CSL Seqirus Logo]

[H2] CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus

[IMG: CSL Vifor Logo]

[H2] CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL Vifor

[H2] Vita: Original Stories

[H3]
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.

[IMG: Melissa, who lives with hereditary angioedema (HAE), shares her patient journey.]

[H3]
Video: Melissa's HAE Story
For decades, the rare disease Hereditary Angioedema (HAE) overwhelmed Melissa’s days. But today she’s making up for lost time…

01 May 2026

[IMG: Makiko Matsuyama, president of Japan’s Hereditary Angioedema (HAE) patient association]

[H3]
What Loss Has Taught Me About Sharing
Makiko Matsuyama, president of Japan’s Hereditary Angioedema (HAE) patient association, discusses the danger of undiagnosed H…

29 Apr 2026

[IMG: Dr. Konrad Bork, a pioneer in hereditary angioedema (HAE) research]

[H3]
An HAE Pioneer Reflects on the Evolution of Care
Dr. Konrad Bork encourages the next generation of physicians to listen to their patients and stay curious. He’s been research…

28 Apr 2026

[IMG: CSL scientist in Switzerland]

[H2] Careers at CSL

We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
Promising Futures at CSL

[H3]
CSL on LinkedIn
Follow us!

[IMG: LinkedIn]
13 May

The experience of hereditary angioedema \(HAE\) can be shaped by years of unanswered questions.
Makiko sadly lost her husband to HAE before he ever received a diagnosis. Her daughter has since been diagnosed with the condition and Makiko now advocates for improved awareness of HAE as Director of the patient group, HAE Japan. She says, “Just knowing ‘I’m not the only one’ helps people face forward a little more.”
With HAE Day taking place in May, we want to recognize the strength of the HAE community, a community CSL has been proud to support for over 45 years. By raising awareness of HAE, we can help more people recognize the signs, seek support earlier, and move closer to the clarity every family deserves.
Find out more about Makiko’s story here:
https://bit.ly/4eBmMv7
#CSL #HAEDay #Active4HAE

[IMG: LinkedIn]
12 May

CSL Seqirus has signed a new multi-year pandemic preparedness agreement with the Pan American Health Organization (PAHO) Regional Revolving Fund to help strengthen pandemic readiness across Latin America and the Caribbean.
Across CSL Seqirus’ 30+ government partnerships globally, this is the first agreement of its kind established in the region, complementing the parties’ recent seasonal influenza agreement.
This agreement lays the foundation for a coordinated pandemic response that ensures the region is ready to respond rapidly when it matters most.
Learn more here: https://bit.ly/4fhCH1V
#CSLSeqirus

[IMG: LinkedIn]
5 May

Delays in diagnosis can hold people back—but earlier action can change lives.
Proud to support World PI Week and share this message from Sujan Sivasubramaniyam, our Head of Global Patient Advocacy & Policy.
#WeCantWait #WorldPIWeek #PrimaryImmunodeficiency

[IMG: LinkedIn]
7 May

Your work at CSL isn’t just a job — it’s a mission.
Every innovation, every breakthrough and every effort helps deliver lifesaving and life-changing medicines to patients worldwide. From pioneering plasma technologies to advancing global health initiatives, our teams are shaping the future of medicine.
Join us and be part of a company where your talent powers progress and transforms lives.
Explore careers: csl.com/careers
#CSL #CSLImpactReport #CSLCareers #PromisingFutures

[IMG: LinkedIn]
5 May

Every milestone brings us closer to transforming lives with innovative treatments for serious and rare diseases. At CSL, we’re not just advancing science — we’re creating hope for patients worldwide.
If you want a career where your work drives progress and makes a real impact, join CSL.
Explore careers: csl.com/careers
#CSL #CSLImpactReport #CSLCareers #PromisingFutures

[IMG: LinkedInPostImage]

[IMG: LinkedIn]
17 Apr

This World Hemophilia Day, we support the World Federation of Hemophilia theme: "Diagnosis: First step to care”.
When symptoms like unexplained bleeding, bruising, heavy periods or joint pain are recognized and diagnosed as a bleeding disorder, timely access to effective care can prevent serious complications.
Yet more than 75% of people with hemophilia worldwide remain undiagnosed. The gap is even greater for von Willebrand disease, rare bleeding disorders, and women and girls.
Early diagnosis and ongoing dialogue are critical to ensuring people with bleeding disorders receive comprehensive care through shared decision making.
Today and everyday, we are proud to be a longtime partner of the World Federation of Hemophilia's Humanitarian Aid Program, supporting its vital work in creating meaningful change, improved outcomes, and lasting progress for individuals, communities, and healthcare systems worldwide. highlighting that diagnosis unlocks access to lifelong care.
Read the WFH Humanitarian Aid Impact Report to learn more: https://bit.ly/4tmZw8m
#CSL #WHD2026 #WorldHemophiliaDay #BleedingDisorders #Haemophilia #VonWillebrandDisease

[IMG: LinkedIn]
28 Apr

At #ChinaBioPartnering in Shanghai, CSL's Head of R&D Search and Evaluation, @[Stephen Pitt, Ph.D.], joined a panel discussion with leading biopharma and venture voices on the new partnering playbook – how collaboration is evolving from traditional asset deals to broader ecosystem alliances.
China’s rapidly advancing biotech sector continues to produce high-impact science, complementing CSL’s clinical and commercial expertise and global reach. Recently, we’ve connected with over 75 local biotech leaders and entrepreneurs in partnering meetings across immunology, hematology, cardiovascular & renal, exploring opportunities to codevelop the next generation of breakthrough medicine.
If you are advancing new therapies with the potential to change patients' lives, CSL would welcome a conversation. We’re a $50 billion global biotech that invests $1.4 billion annually in R&D to deliver therapies and vaccines to people in over 100 countries. #CSL

[IMG: LinkedIn]
6 May

Partnerships are becoming a core driver of how quickly innovation can be translated into development decisions and, ultimately, patient impact. In CSL's panel discussion at #SwissBiotechDay 2026, Hervé Gisserot and Memo Therapeutics AG reflect how we tailor partnership models across the lifecycle, from platform optionality to late stage execution readiness.
And for partners, CSL brings value beyond funding: development expertise, regulatory and access strategy, governance and launch planning to help de-risk execution and deliver patient impact.
#CSL

[IMG: LinkedIn]
6 May

Three CSL employees from the U.S. spent a week in Guatemala, building purpose-built dialysis rooms in the homes of two pediatric patients.
Click the link to learn more: csl.com/impact
#CSL #CSLImpactReport #KidneyRelatedConditions

[IMG: LinkedIn]
25 Apr

📕📕📕Free book alert! It's World PI Week - a great time to get your free download of "More than a Patient," a new book by Jodi Taub, who is both a #primaryimmunodeficiency patient and an experienced therapist who works with patients who have rare and chronic diseases. Visit https://www.csl.com/book to download. #CSL #MoreThanAPatient #WorldPIWeek #PI #raredisease #ChronicIllnessAwareness #immunocompromised

[IMG: LinkedInPostImage]

[IMG: Manufacturing in Holly Springs]

[H1] Our Businesses and Products

[H2] Always Evolving for a Better World

For over a century, we’ve been an unstoppable force, from developing medicines that save and improve lives to vaccines that protect them. Today, with the combined expertise of CSL Behring (with oversight to CSL Plasma), CSL Seqirus, and CSL Vifor—and our singular commitment to relentlessly innovate—CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they deserve. We’re always improving so life can, too.

[IMG: CSL Behring Logo 2022]

Our Products

[IMG: CSL Seqirus Logo]

CSL Seqirus Products

[IMG: CSL Vifor Logo]

CSL Vifor Products

[H2] Commitment to Quality

At CSL, we are Driven by Our Promise and guided by our Values: Patient Focus, Innovation, Integrity, Collaboration and Superior Performance. These are evident in every aspect of our global business and support our Commitment to Quality.
CSL is committed to protecting public health and improving and saving the lives of patients with rare and serious diseases through the development, manufacture and reliable supply of high-quality medicines.
Our Quality Management System provides the framework for ensuring adherence to global regulatory requirements for the entire product life cycle across the globe. The QMS contains policies and procedures to manage our business processes across all functions, our partners and suppliers, product manufacture, distribution and sales, and the ongoing monitoring of product safety in the field.
People are the core of CSL's quality culture. CSL employees recognize their individual responsibility to insist on the quality and safety of our products, protect public health and ensure the safety of our plasma donors. Engagement and education of CSL employees is key to sustaining the highest standards throughout the company.
The commitment of our people to Quality within our Values-based work environment is essential to delivering on our promise to the public and our patients.

[IMG: Vials in Fill and Finishing]

[H1] Rare & Serious Diseases

[H2] Our Promise to Patients

[IMG: Roberta Smith]
vWD Patient Roberta Smith

CSL is committed to putting the patient first in all that we do to discover, develop, and deliver biotherapeutics and vaccines that meet their needs.
We know that every patient is someone’s child, parent, grandparent, family member, friend or colleague. We also understand that rare and serious diseases impact more than just the patient. They also impact their loved ones and the communities that support them.
With that in mind, we strive to deliver therapeutics that meet patient needs, as well as build support systems to create empowerment and community through various programs and activities around the world. We also partner with patient advocacy organizations to inform our development efforts and to improve and expand outreach, education and access to medicines and resources.
Our patients are our passion and that drives the way we work. We are committed to full transparency of expectations and outcomes when partnering with them. We listen closely to patients about their lived experiences and collaborate with them from early research through the delivery of our innovative medicines. We seek to fully understand their challenges to ensure our research is relevant, meaningful and leads to therapies that result in outcomes that are important to them and make a difference in their lives.
Our people are the heart of our Patient Focus culture and we strive to earn our patients’ trust every day. CSL employees understand that they are personally accountable for ensuring our interactions with patients are responsible, respectful and humble. We recognize patients as the experts in how diseases impact their lives and we actively seek their insights to guide our efforts and inform our choices.
The commitment of our people to Patient Focus as part of our Values-based culture is essential to delivering on our promise to patients and improving public health.

[H2] Find Your Disease

[H3] Immunodeficiency & Autoimmune Diseases

We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Guillain-Barré Syndrome (GBS)
Idiopathic Thrombocytopenic Purpura (ITP)
Kawasaki Disease (KD)
Primary Immunodeficiency
Secondary Immunodeficiency (SID)

[H3] Hereditary Bleeding Disorders

We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:

Factor X Deficiency
Factor XIII Deficiency
Fibrinogen Deficiency
Hemophilia A
Hemophilia B
Von Willebrand Disease

[H3] Hereditary Angioedema (HAE)

We introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.

Read more about Hereditary Angioedema (HAE)

[H3] Alpha 1 Antitrypsin Deficiency

Our Alpha 1 Antitrypsin treats Alpha 1 Antitrypsin Deficiency (AATD) in patients with AATD-related emphysema.

Read more about Alpha 1 Antitrypsin Deficiency

[IMG: A Family of four playing outdoors in the grass and sunshine]

[H1] Healthier Communities

[H2] Creating Healthier Communities that Benefit all

Meeting the needs of people, patients and communities is the reason we exist. From developing new, innovative therapies for diseases to enabling greater access to life-saving vaccines, protecting the health and wellbeing of our patients and communities around the world sits at the center of our purpose as a business. This includes a heartfelt commitment to the safety and trust of our donors, who make vital therapies possible, and to continuous engagement with the stakeholders we depend upon to fulfill our promise.
CSL understands that when it aligns its efforts with core expertise and business goals, addressing priority focus areas and material topics in the context of the business and the industry, it can have the greatest positive impact. CSL has continued to evolve its sustainability strategy, with the goal of deploying its resources to service stakeholders in the focus areas of Access and Affordability, Patient Experience and Donor Experience.
This is CSL’s commitment to ‘Healthier Communities’, because it recognises that healthier communities benefit all.
CSL’s healthier communities focus areas and commitments include:

Focus Area
Commitments

Access and Affordability
CSL is committed to advancing equitable access to its medicines and vaccines by designing access and affordability programs to serve vulnerable populations and expand strategic donations:

Through extension of CSL’s existing World Federation of Haemophilia (WFH) partnership, by FY2030, CSL aims to donate products that enable 2,100 people with bleeding disorders to access prophylaxis therapy across 25 low- and middle-income countries.
In support of reaching more communities and patients, through discounted products, CSL has announced a new aspirational commitment to treat up to 450,000 people with anaemia in at least three low- and middle-income countries with CSL Vifor’s Ferinject® by FY2030.

Patient Experience
CSL’s commitment is to elevate the Patient Experience in drug development by embedding patient insights and lived experience through patient-informed clinical development programs and formalising plans to include representative populations.
CSL’s commitment for FY2030:

Informed Product Development: all of CSL’s therapeutic product development programs are informed by patient insights.
Representative Clinical Trials: Phase III clinical trials incorporate participants that are representative of the target indicated population.

Donor Experience
CSL’s ambition is to create best-in-class donor experience in partnership with donors and communities, by continuously innovating the donation process, supporting donors’ holistic well-being, and investing in the health equity of donor communities.
CSL’s commitment for FY2030 is to initiate new programs to promote health awareness resources, ensuring that at least 30% of donors obtain access.
Furthermore, CSL intends to increase donor satisfaction survey results, utilising a new customer satisfaction methodology to be implemented and baselined in FY25.

[H2] CSL's Community Contributions Framework

Focus Area
Focus Area Description
Alignment with our Values and 2030 Strategy

Support for Patient Communities

Enhancing quality of life for patients in the conditions our therapies treat
Improving access to our medicines

Aligns with CSL’s Values of Patient Focus and Integrity.
Supports CSL’s Patient and Public Health and Focus strategic objectives by improving patient outcomes.

Support for Innovation and Science

Advancing knowledge in medical and scientific communities
Fostering the next generation of medical researchers

Aligns with CSL’s Values of Innovation and Collaboration.
Supports CSL’s Innovation strategic objective by fueling new breakthroughs, enhancing scientific knowledge and building capability and capacity.

Support for Local Communities

Supporting community efforts where we live and work
Supporting communities in times of emergency

Aligns with CSL’s Value of Superior Performance.
Supports CSL’s People and Culture strategic objective by creating an environment that employees feel proud to perform within.

Our approach to community contributions is guided by our Code of Conduct and Global Community Contributions Policy. The policy applies to all CSL businesses and employees and is intended to be implemented across the businesses to guide decision-making and management of any form of community contribution, financial or by other means.

[IMG: 20190726_Seqirus_PKV_0041]

[H2] Learn more about our work on:
Product Safety & Quality
Innovation & R&D
Access & Affordability
Responsible & Resilient Supply Chain
Donor Experience
Patient Experience

[IMG: CSL]

[H1] Early Careers at CSL
Pictured: Graduate Program Participants in Australia

[H2] Early Career Programs at CSL

[H3] Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising FUTURE. Find yours here.

[IMG: CSL Apprentices]

[H3] Apprenticeships

Prepare for your professional future and gain a better understanding of the types of careers available at CSL with a work-and-study program.

Pictured: Apprentices in Marburg, Germany

View Apprenticeships

[IMG: CSL Co-ops]

[H3] Internships, Co-ops and Dual-study Programs

We offer internships, cooperative education (co-op) experiences, and dual-student programs for university students.

Pictured: Interns and co-ops in King of Prussia, United States

View Programs

[IMG: Image of CSL Graduates in front of a building at the Parkville site]

[H3] Rotational Programs

Our rotational programs are designed for those at the post-university level looking to gain the skills and knowledge needed for a successful career.

Pictured: Graduate students in Melbourne, Australia

View Rotational Programs

[IMG: Promising Futures]

[IMG: R&D Scientist in Parkville]

[H1] Careers at CSL
Pictured: CSL Seqirus employee in Australia

[H2] CSL Offers Promising Futures

[IMG: CSL Family of Companies]

As a global biotech leader we are a diverse collective of dedicated people exploring every avenue, every day, to achieve one shared goal—to reimagine, reinvent and be ever inspired to find new and more effective ways to save, improve and protect life.
Learn more about CSL by watching our short Promises video.

[IMG: Woman with microscope]

[H2] Earning more than a paycheck: Learn about our benefits

We offer flexible working schedules, robust career and development tools, a global employee share plan, study assistance and more. Come grow your career with us.
Pictured: CSL Seqirus manufacturing employee
Learn About How We Support Your Well-being

[IMG: Employees from Parkville]

[H2] Reflecting the world around us

We embed inclusion and belonging in everything we do – from how we attract talent and support our employees to how we engage with the communities in which we live and work.
Pictured: CSL employees in Melbourne, Australia
Learn About Our Inclusion and Belonging Strategy

[H2] Interview Tips from CSL Employees

Hear tips and tricks about how to prepare for an interview with CSL, directly from current employees.
Pictured: CSL Behring employee in the United States
Watch video

[H2] CSL: A Great Place to Work

[H3] CSL Named to Forbes Global 2000

CSL Ranks Among the Top 500

[H3] CSL Listed Among America’s Best Employers

Forbes Magazine Ranks Large Employers

[H3] CSL Named One of the World’s Best Employers for 4th Year in a Row

Forbes Magazine Ranks 750 Large Companies

[H2] Vita: Original Stories

[H3]
Read our career-focused stories about life at CSL.

[IMG: CSL donates $100,000 to tornado relief in Kankakee, Illinois. Image of employees and local officials holding check.]

[H3]
CSL Donates $100,000 to Kankakee Tornado Relief
We stand with the Kankakee community in support of cleanup and rebuilding efforts.

30 Mar 2026

[IMG: Women Leading Change - images of six women who work in CSL manufacturing]

[H3]
Video: Hear from Women in Manufacturing
How do you lead through change and stay focused on progress? In honor of International Women’s Day, we interviewed leaders to…

06 Mar 2026

[IMG: A young man who is benefiting from the WFH Humanitarian Aid program for hemophilia patients]

[H3]
On the Ground in Uzbekistan
On a trip supporting the World Federation of Hemophilia’s Humanitarian Aid Program, CSL’s Senior Director of Global Policy an…

04 Feb 2026